NVIDIA Corporation (NASDAQ:NVDA) received a boost from UBS, which reaffirmed a Buy rating on the stock, setting a target price of $205.00. This decision...
URGENT UPDATE: UBS has officially downgraded its rating for Novo Nordisk, the renowned Danish pharmaceutical company behind the blockbuster weight-loss drugs Ozempic and Wegovy....
UPDATE: Swiss banking giant UBS has just announced a stunning quarterly profit of $2.395 billion for the second quarter, far exceeding analyst expectations. This...